Nuglim M 2mg/500mg Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making Nuglim M effective in patients inadequately controlled by diet and exercise alone. The prolonged-release formulation ensures a steady release of active ingredients, optimizing therapeutic efficacy and minimizing gastrointestinal side effects commonly associated with metformin. Nuglim M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is essential to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Nuglim M 2mg/500mg Tablet PR should be used under medical supervision to achieve optimal glycemic control and reduce the risk of diabetes-related complications.